Drug intelligence / Profile preview

efinaconazole

Development stage: Approved
Lead developer: Kaken Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

Efinaconazole is a triazole antifungal medication indicated for the topical treatment of onychomycosis (fungal infection of the toenails), primarily caused by *Trichophyton rubrum* and *Trichophyton mentagrophytes*. It acts by inhibiting lanosterol 14-alpha demethylase, an enzyme involved in ergosterol biosynthesis, which is essential for maintaining fungal cell membrane integrity. Efinaconazole was first approved in 2014 and is marketed under the brand name Jublia. The drug is applied as a 10% topical solution and has demonstrated efficacy in clinical trials for achieving complete or almost complete cure rates in patients with toenail onychomycosis[3][4][5][6][8].

Brand names: Jublia
Other names: evonail

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on efinaconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on efinaconazole.

Explore the full profile